# Olanzapine in Patients With Borderline Personality Disorder

> **NCT00091650** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 300 (—)

## Conditions studied

- Borderline Personality Disorder

## Interventions

- **DRUG:** Olanzapine
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00091650
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** —
- **Final completion:** 2005-11
- **Target enrollment:** 300 (—)
- **Last updated:** 2006-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00091650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00091650, "Olanzapine in Patients With Borderline Personality Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00091650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*